Navigation Links
Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
Date:4/7/2008

TORONTO, April 7 /PRNewswire/ - Medical Futures Inc. has licensed MUTAFLOR(R) for the North American market. MUTAFLOR(R) is a drug used in remission maintenance of Ulcerative Colitis. Since its discovery in 1917, MUTAFLOR(R) has been available in the German marketplace through a subsidiary of Pharma-Zentrale GmbH, Ardeypharm GmbH. MUTAFLOR(R) has shown clinical efficacy in phase III clinical trials and has shown a perfect safety record since 1917. Ulcerative colitis is an Inflammatory Bowel Disease that affects 500,000 Americans and 60,000 Canadians.

"Medical Futures Inc. is excited about partnering with Pharma-Zentrale GmbH for MUTAFLOR(R)," says Dr. Par Nijhawan, Chief Medical Officer of Medical Futures Inc., who believes that MUTAFLOR(R) will help improve the options available for Ulcerative Colitis patients.

"Medical Futures has created a therapeutic focus and a strong product offering for the gastroenterology market in North America," says Hans Proppert, President and Chief Executive Officer of Pharma Zentrale GmbH. "With MUTAFLOR(R) in their capable hands, we are confident of its success in an important market for us."

About MUTAFLOR(R)

MUTAFLOR(R) has data proving equal efficacy when compared to 5-ASA products in remission maintenance of Ulcerative Colitis. It is taken as an oral capsule format that saves patients from intravenous infusions or self administration of subcutaneous needles. This, together with the clinical evidence, is one advantage of MUTAFLOR(R) over all other biologics available on the market.

About Medical Futures Inc.

Medical Futures Inc. is a niche pharmaceutical company that has a focus on gastrointestinal therapy. Medical Futures is dedicated to improving quality of life and provides safe, effective and affordable medicines. These medicines include:

Florastor(TM): The world's number one probiotic that has proven efficacy in treating and preventing diarrhea from various causes including Pediatric Diarrhea, Antibiotic Associated, Clostridium Difficile and Travellers' Diarrhea.

Iberogast(R): The only treatment available for Non-ulcer Dyspepsia and Irritable Bowel Syndrome.

Zingo(TM) is a needle-free, easy-to-administer, single-use system that delivers sterile lidocaine powder into the epidermis of the skin that provides topical, local analgesia in one minute.

SANVAR(R) is the only somatostatin analogue to have demonstrated statistically significant benefits in the treatment of esophageal variceal bleeding in association with endoscopic therapy in a placebo-controlled clinical study (NEJM, 2001).


'/>"/>
SOURCE Medical Futures Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management software ... provides a cloud hosted environment for FileHold software that is pay per user ... party applications using the FileHold web services API. DocuSyst also advises clients on ...
(Date:2/8/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a product ... from a cluster of melanin when exposed to sunlight. Although most moles are benign ... of embarrassment. Historically, mole removal has involved a painful, often expensive visit ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... four states in the U.S. require dental technicians to be certified or obtain ... dental industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and Kevin Harrington, along ... new DRTV campaign with Belly Bands. , Having a dog is great—except when it ... pads and find nothing works, get Belly Bands, the easiest way to stop ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... http://www.researchandmarkets.com/research/bcrl3s/labelfree ) ... "Label-Free Detection Market by Technology, Products, Applications ... to their offering. --> http://www.researchandmarkets.com/research/bcrl3s/labelfree ... "Label-Free Detection Market by Technology, Products, ... report to their offering. --> ...
(Date:2/8/2016)... 8, 2016  Astellas Pharma Inc. President and Chief Executive ... James Robinson as president, Americas Operations, for Astellas ... and South America , effective April 1, ... the commercial organization in the United States ... Masao Yoshida , who is retiring in June 2016.  ...
(Date:2/8/2016)... 2016  LivaNova, PLC, Hersteller des VNS-Therapie ... dem Titel „Epilepsy Around the World" (Epilepsie ... Krankheit gegenüber ein größeres Bewusstsein gefördert werden ... bei Epilepsie auf dem Internationalen Epilepsietag zu ... Mithilfe der neuen Infografik sollen wichtige Statistiken ...
Breaking Medicine Technology: